TG THERAPEUTICS INC (TGTX)
Health Care · Immunology / Neurology Therapeutics · NASDAQ
Commercial-stage biotech focused on anti-CD20 monoclonal antibody therapies for B-cell diseases, with FDA-approved BRIUMVI for relapsing multiple sclerosis and expanding pipeline in neurology.
What TG THERAPEUTICS INC does
TG Therapeutics is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. The company's lead product, BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody, received FDA approval in December 2022 for adult patients with relapsing forms of multiple sclerosis (RMS) and launched commercially in the U.S. in January 2023. TG Therapeutics is expanding its pipeline to evaluate subcutaneous formulations of ublituximab, simplified dosing schedules for BRIUMVI, and investigational programs in myasthenia gravis and progressive multiple sclerosis.
Themes: []
Fundamentals
- Price$59.06 as of 2026-07-09 close
- Market cap$8.8B as of 2026-07-10
- 1-year return+55.7% as of 2026-07-09 close
- P/E18.97 as of 2026-07-10
- Net margin+66.0% as of 2026-07-10
- Gross margin+83.0% as of 2026-07-10
- ROE+87.4% as of 2026-07-10
- Debt / equity1.28 as of 2026-07-10
- Revenue growth (YoY)+81.3% as of 2026-07-10
- Revenue CAGR (3y)+504.9% SEC XBRL
- Beta1.65 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.